Trial Profile
A randomized phase 2 clinical trial of docetaxel with or without PF-3512676 [agatolimod] as first-line treatment of patients with advanced breast cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Agatolimod (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Nov 2007 Status changed from in progress to withdrawn prior to recruitment.
- 28 Aug 2007 Status changed from initiated to in progress.
- 18 Jul 2007 New trial record.